You are here
Dr Ryan Toh
Ryan completed his PhD in the Department of Paediatrics, University of Melbourne in 2017. He started his role as an Research Officer in the New Vaccines Research Group in 2018 under the supervision of Professor Kim Mulholland and Associate Professor Paul Licciardi.
Ryan's research interests include exploring alternative human papillomavirus (HPV) vaccination strategies such as reduced-dose schedule and targeted vaccination of high-risk groups, to improve vaccine uptake in resource-limited settings. He has been involved in several vaccine clinical trials and has acquired considerable experience in a number of microbiological and immunological techniques. He has presented at numerous scientific meetings and published more than 20 manuscripts and book chapters. He has supervised 3 Honours student and currently supervising a Master student.
Honorary Research Fellow, Department of Paediatrics, University of Melbourne
1. Examining the immunogenicity of human papillomavirus vaccine following reduced-dose schedules
2. Evaluation of HPV vaccine immunity in high-risk women: A pilot study
1. Toh ZQ, Kosasih J, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu FT, Nguyen CD, Matanitobua S, Do LAH, Menheniott T, Frazer IH, Garland SM, Mulholland EK, Licciardi PV. Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules. Vaccines (Basel). 2019 Nov 28;7(4). pii: E200. doi: 10.3390/vaccines7040200.
2. Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019 Jul 4;12:1951-1967. doi: 10.2147/IDR.S178381.
3. Toh ZQ, Cheow KWB, Russell FM, Hoe E, Reyburn R, Fong J, Tuivaga E, Ratu FT, Nguyen CD, Matanitobua S, Reitsma A, Tabrizi SN, Garland SM, Mulholland EK and Licciardi PV. Cellular immune responses 6 years following 1, 2 or 3 doses of quadrivalent HPV vaccine in Fijian girls, and subsequent responses to a dose of bivalent HPV vaccine. Open Forum Infectious Diseases, ofy147, 2018 June 20. https://doi.org/10.1093/ofid/ofy147
4. Toh ZQ, Licciardi PV, Russell FM, Garland SM, Batmunkh T, Mulholland EK. Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia. Asian Pac J Cancer Prev. 2017 Sep 27;18(9):2339-2343.
5. Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, Nguyen CD, Devi R, Kama M, Matanitobua S, Tabrizi SN, Garland SM, Sinha R, Frazer I, Tikoduadua L, Kado J, Rafai E, Mulholland EK, Licciardi PV. Sustained antibody responses six years following one, two, or three doses of quadrivalent HPV vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clin Infect Dis (2017) 64 (7): 852-859. DOI: https://doi.org/10.1093/cid/ciw865. Published: 28 December 2016
6. Licciardi PV, Hoe E, Toh ZQ, Balloch A, Moberley S, Binks P, Marimla R, Leach A, Skull S, Mulholland EK and Andrews R. Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians. Clin Transl Immunology. 2017 Oct; 6(10): e158. doi: 10.1038/cti.2017.46
8. Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK., Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Vaccine. 2015 Sep 22;33(39):5042-50.
2. MCRI Internal theme grant 2019